Indivina (Medroxyprogesterone Acetate, Estradiol Valerate)

Medroxyprogesterone acetate binds to progesterone receptors in target tissues, delivering progestogenic effects that counterbalance estrogen‑driven endometrial proliferation. This action reduces the risk of uncontrolled uterine bleeding when estrogen is administered concurrently.

The specific dose and dosing schedule of Indivina are determined by the prescribing clinician based on the patient’s age, clinical condition, and therapeutic goals. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Indivina is not recommended for use during pregnancy or while breastfeeding because the hormonal components can affect fetal development and milk production. Women of child‑bearing potential should use effective contraception and discuss any pregnancy plans with their healthcare provider.

To order Indivina, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Indivina delivers both estradiol (a natural estrogen) and medroxyprogesterone acetate (a synthetic progestogen), whereas many other HRT products use synthetic estrogens such as ethinyl estradiol. The natural estradiol component may provide a metabolic profile closer to endogenous hormones, but individual response varies and should be evaluated by a clinician.

Indivina tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat, and direct sunlight to maintain potency throughout the shelf life.

Indivina is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, cardiovascular complications like stroke or myocardial infarction, severe liver dysfunction, and allergic reactions. Patients should seek immediate medical attention if they experience unexplained leg pain, shortness of breath, chest pain, severe abdominal pain, or signs of an allergic reaction.

Indivina is contraindicated in women with a history of estrogen‑dependent cancers (e.g., breast or endometrial cancer), active or past thromboembolic disease, uncontrolled hypertension, severe liver disease, or known hypersensitivity to either component. It should also be avoided during pregnancy and lactation.